Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

January 2017 Issue of The Medicine Maker

Welcome to the January issue. Upfront investigates the relationship between pharma and patients, Donald Trump’s attack on pharma, and chemically functionalized spider silk. In our cover feature, we quiz past contributors for their opinions on 2016 – and ask them what priorities and resolutions the industry should focus on for 2017. NextGen explores modeling in bioprocess development, and in Profession, Rafaat Rahmani explains how he built an award winning global company from the ground up. We also sit down with Dominic Carolan, CEO of the National Institute for Bioprocessing Research and Training (NIBRT).

Register to download

Register here to download any issue of The Medicine Maker for FREE.

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Articles featured in this issue

Manufacture Business Practice

Failure to Engage

| Stephanie Sutton

Could public health suffer if the pharma industry doesn’t learn to win back trust?

Discovery & Development Analytical Science

Relating the Geno to the Pheno

| James Strachan

Health data analytics help unravel the biology behind Alzheimer’s and Schizophrenia.

Discovery & Development Drug Delivery

Oh, What a Wonderful Web We Weave

| James Strachan

Could chemically functionalized spider silk be used for innovative drug delivery?

Manufacture Technology and Equipment

A Bad Relationship

| James Strachan

Our infographic shows the huge disconnect between patients and drug manufacturers.

Business & Regulation Business Practice

Trump Targets Pharma

| James Strachan

“We’re going to start bidding,” says Trump. Are we about to see changes to Medicare?

Business & Regulation Business Practice

Business-in-Brief

| James Strachan

A patent surprise, authorization denied, and EpiPen’s monopoly compromised...

Discovery & Development Clinical Trials

Parents Pass Placebos

| James Strachan

Is it ethical to use placebo controls in pediatric clinical trials?

Business & Regulation Business Practice

Pressure Cooker Pricing

Marathon Pharmaceuticals’ pricing of Emflaza for Duchenne muscular dystrophy causes controversy

Business & Regulation Biosimilars

Biosimilars, Come Fly With Me

| Catherine Godrecka-Bareau

How inspiration from the airline industry could help improve the biosimilars industry.

Discovery & Development Packaging

The Perfect Package

| Ajith Nair

Are current guidelines around packaging and product degradation up to scratch?

Manufacture Analytical Science

Standing Up for Microcalorimetry

| Natalia Markova

We investigate the advantages and limitations of microcalorimetry in biopharma.

Manufacture Business Practice

Revelations and Resolutions

| Stephanie Sutton

What was hot in 2016? And what should pharma's priorities lie in 2017?

Manufacture Quality & Compliance

The Bioprocess Model Maker

| Jarka Glassey

What separates a good model from a bad model in bioprocess development?

Business & Regulation Business Practice

Is Flexibility the Way Forward for Female Leaders?

| Rosalie Harrison and June Nilsson

Men continue to dominate upper management positions, but could flexible working change this?

Business & Regulation Business Practice

Walking the Entrepreneur's Path

| Rafaat Rahmani

It’s not easy finding your way “from a garage to a palace...”

Business & Regulation Business Practice

Is the Price Right?

| George A. Chressanthis

Pharma needs new business model designs and analytics to help measure value.

Business & Regulation Business Practice

Leading the Way

| Dominic Carolan

Sitting Down With Dominic Carolan, CEO of NIBRT.

Discovery & Development Analytical Science

Putting Peptides on the Map

Streamlined workflows help scientists plot a course for painless peptide mapping

Other issues of 2017